Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05208190 · ClinicalTrials.gov registry record · Phase 4
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
A Phase 4 study of Schizophrenia and Schizoaffective Disorder, sponsored by New York State Psychiatric Institute.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 280
- Enrollment target
- 7
- Study locations
NCT05208190: Recruiting Phase 4 study of Schizophrenia and Schizoaffective Disorder, sponsored by New York State Psychiatric Institute.
NCT05208190 is a Phase 4 study of Schizophrenia and Schizoaffective Disorder that is actively recruiting participants, run by New York State Psychiatric Institute. The registered enrollment target is 280 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (28% higher). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05208190, a Phase 4 study of Schizophrenia and Schizoaffective Disorder, is actively recruiting participants, sponsored by New York State Psychiatric Institute.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 280 participants
- Enrollment target
- 7
- Study locations
Study Summary
Two-hundred and eighty individuals with schizophrenia who have a recent history of violent acts will be randomized in this 2-arm, parallel-group, 24-week, open-label, 7-site clinical trial to examine the effects of treatment with clozapine vs antipsychotic treatment as usual (TAU) for reducing the risk of violent acts in real-world settings
Primary Outcome
violent acts as measured by the MacArthur Community Violence Interview
Conditions Studied
Interventions
- DRUG Clozapine
- DRUG treatment as usual
Study Locations (7)
New York
- NYU Langone Medical Center - New York
- New York State Psychiatric Institute - New York
- Manhattan Psychiatric Center - New York
California
- University of California, Los Angeles - Los Angeles
Georgia
- Augusta University Research Institute, Inc. - Augusta
Maryland
- University of Maryland School of Medicine - Baltimore
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2022-03-17 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 4 |
What NCT05208190 shows while recruiting
NCT05208190 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (28% higher).
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Clozapine is the first listed.
NCT05208190 lists 7 locations in 5 states (New York, California, Georgia).
Frequently Asked Questions
What is clinical trial NCT05208190 about?
NCT05208190 is a clinical study titled "Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial". Two-hundred and eighty individuals with schizophrenia who have a recent history of violent acts will be randomized in this 2-arm, parallel-group, 24-week, open-label, 7-site clinical trial to examine the effects of treatment with clozapine vs antipsychotic treatment as usual (TAU) for reducing the r...
What is the current status of trial NCT05208190?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 280 participants. The study started on 2022-03-17. Estimated completion is 2028-12-31.
What conditions does trial NCT05208190 study?
This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder.
What interventions are being tested in trial NCT05208190?
The interventions under investigation include: Clozapine (DRUG), treatment as usual (DRUG).
Who is sponsoring clinical trial NCT05208190?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05208190 being conducted?
This trial has 7 study locations across California, Georgia, Maryland, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05208190's enrollment target sits among peer trials
280 71st of 315 higher than 244 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
CLOZAPINE Response in Biotype-1
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Anti-Inflammatory Challenge in Schizophrenia
RECRUITING · Phase 4
-
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI